Indication
Filspari is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion > 1.0 g/day (or urine protein-to-creatinine ratio > 0.75 g/g, see section 5.1).
Loading your page…
Loading your page…
Glomerulonephritis, IGA
Marketing Authorisation Holder: Vifor France
EMA Authorisation: 19/04/2024
INN: sparsentan
AI Drug & Interaction Analysis
Free account required
Ask Osler about Filspari: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.